US Patent:
20120009201, Jan 12, 2012
Inventors:
Josip Blonder - Frederick MD, US
Donald J. Johann - Bethesda MD, US
Timothy D. Veenstra - Jefferson MD, US
International Classification:
A61K 39/395
C12Q 1/68
C12Q 1/37
G01N 33/53
G01N 33/574
C07K 16/40
C07K 16/18
C07H 21/00
A61P 35/00
C40B 30/04
A61K 31/713
US Classification:
4241581, 506 9, 435 613, 435 612, 435 23, 435 71, 514 44 A, 4241741, 4241781, 5303897, 536 2431, 435 792
Abstract:
Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker.